These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15522063)

  • 21. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
    Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
    Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
    Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
    Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
    Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
    Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
    Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
    Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hairy cell leukemia: an elusive but treatable disease.
    Wanko SO; de Castro C
    Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hairy cell leukemia with cladribine].
    Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
    Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences).
    Chrobák L; Podzimek K; Zak P; Plísková L; Voglová J
    Acta Haematol Pol; 1995; 26(2 Suppl 1):56-62. PubMed ID: 7653236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
    Orciuolo E; Buda G; Sordi E; Baraté C; Galimberti S; Ciancia E; Petrini M
    Leuk Res; 2010 Feb; 34(2):184-9. PubMed ID: 19414190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.